Actemra IV (tocilizumab) / Roche, JW Pharma - LARVOL DELTA

Case Report: Intra-articular injection of tocilizumab for arthritis treatment in chronic graft-vs.-host disease. (PubMed, Front Pediatr) - "He was administered anti-rejection drugs with cyclosporine, ruxolitinib, and methylprednisolone by his physician, which did not work. After treatment for 4 months, the patient could walk a few hundred meters with minimal exertion. An intra-articular injection of tocilizumab could be a viable treatment option for arthritis; however, large-scale clinical trials are warranted to confirm its efficacy."

Journal • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Novel Coronavirus Disease • Oncology • Rheumatology • Transplantation • IL6

DOBERMANN: Low-Dose Dobutamine and Single-Dose Tocilizumab in Acute Myocardial Infarction With High Risk of Cardiogenic Shock (clinicaltrials.gov) - P2 | N=100 | Active, not recruiting | Sponsor: Rigshospitalet, Denmark | Recruiting ➔ Active, not recruiting

Enrollment closed • Cardiovascular • Myocardial Infarction

Teclistamab-associated cytokine release syndrome in multiple myeloma: a case-based literature review of mechanisms, management, and clinical implications. (PubMed, Arch Clin Cases) - "The patient had previously achieved remission with rituximab, bortezomib, and autologous stem cell transplantation but experienced a relapse after eight years...Before treatment, she received premedication with intravenous fluids, steroids, and tocilizumab...This case uniquely contributes to current understanding by highlighting the limitations of current premedication protocols and emphasizing the critical need for enhanced monitoring and rapid intervention protocols in managing Teclistamab-induced CRS. It highlights the critical need for prompt, targeted intervention to prevent fatal outcomes in patients receiving novel immunotherapies."

Journal • Critical care • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Inflammation • Leukopenia • Multiple Myeloma • Oncology • Pneumonia • Respiratory Diseases • Septic Shock • Systemic Inflammatory Response Syndrome • Transplantation • CSF2 • IFNG • IL10 • IL2 • IL6

Anti-NMDAR encephalitis triggered by EBV and HSV-1: A case report and literature review. (PubMed, Medicine (Baltimore)) - "This case is the first diagnosed at our hospital and represents a rare instance in the literature of anti-NMDAR encephalitis directly triggered by co-infection with EBV and HSV-1. The diagnostic process emphasizes the need to maintain a high level of suspicion and repeat antibody tests in patients suspected of autoimmune encephalitis, even when initial antibody tests are negative."

Journal • Review • CNS Disorders • Epilepsy • Epstein-Barr Virus Infections • Herpes Simplex • Immunology • Infectious Disease • Oncology

Turkish Society for Rheumatology (Turkish Takayasu Arteritis Study Group) recommendations for the diagnosis, follow-up and the treatment of Takayasu's arteritis. (PubMed, Clin Exp Rheumatol) - "The first Turkish Takayasu Arteritis Study Group recommendations deriving from a current literature review and large clinical experience, aim to guide clinicians not only in Turkey, but also in other countries who are providing health care to patients with TAK."

Journal • Oncology • Rheumatology • Vasculitis

Potential Predictors of the Outcome of Tocilizumab Treatment in Patients with COVID-19-Associated Hyperinflammation. (PubMed, Infect Dis Clin Microbiol) - "Anakinra treatment was given to 22 patients whose inflammatory parameters did not resolve with tocilizumab. Analysis of this cohort indicated that neutrophil count, CRP, D-dimer, LDH, troponin, and creatine kinase levels may serve as predictors of tocilizumab efficacy on Day 5. The score developed to diagnose HIC can also be used for monitoring treatment response."

Journal • Infectious Disease • Inflammation • Novel Coronavirus Disease • CRP

Multiorgan Failure Resembling Grade 5 (Fatal) Cytokine Release Syndrome in Patient with Multiple Myeloma Following Carfilzomib Infusion: A Case Report. (PubMed, J Clin Med) - "Before the second dose, the patient developed worsening pancytopenia, prompting the discontinuation of Lenalidomide...Despite aggressive management with intravenous fluids, broad-spectrum antibiotics, corticosteroids, and tocilizumab, the patient progressed to refractory shock and multi-organ failure, culminating in death within 24 h. A comprehensive infectious workup was negative, ruling out sepsis and suggesting possible Carfilzomib-induced CRS. Grade 5 multiorgan failure with signs and symptoms similar with CRS following Carfilzomib administration is a rare but potentially fatal adverse drug reaction. Further research is needed to better define the risk factors and optimal management strategies for Carfilzomib-induced multiorgan failure and possible CRS."

Journal • Cardiovascular • CNS Disorders • Hematological Disorders • Hematological Malignancies • Hypotension • Infectious Disease • Inflammation • Multiple Myeloma • Oncology • Pain • Septic Shock

Upadacitinib (Rinvoq) for giant cell arteritis. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Giant Cell Arteritis • Immunology

Impact of Biologic Drugs on Comorbidity Outcomes in Rheumatoid Arthritis: A Systematic Review. (PubMed, J Clin Med) - "The bDMARDs studied were tumor necrosis factor inhibitors (TNFis) (n = 9); Rituximab (n = 5); Tocilizumab (n = 5); Abatacept (n = 5); and Anakinra (n = 2). For instance, selecting biologics such as Anakinra or Tocilizumab might be advantageous for RA patients with concurrent diabetes or anemia, given their observed metabolic and hematologic benefits. This personalized approach could improve the quality of life and reduce healthcare costs by addressing RA and associated comorbidities more effectively."

Journal • Review • Asthma • Cardiovascular • Chronic Obstructive Pulmonary Disease • Diabetes • Hematological Disorders • Immunology • Inflammatory Arthritis • Interstitial Lung Disease • Metabolic Disorders • Oncology • Pulmonary Disease • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Type 2 Diabetes Mellitus

Disparate Roles of Cell-Cell Contact and Cytokine Secretion in an In Vitro Model of the Seminoma Microenvironment. (PubMed, Int J Mol Sci) - "To explore the role of direct cell-cell interaction and the effects mediated by soluble mediators such as cytokines, we conducted co-culture experiments of TCam-2 cells with purified human T cells or monocytes, including Transwell assays and treatments with IL-6, TNFα, or their respective blocking antibodies Tocilizumab and Adalimumab. Nonetheless, we also unveiled the role of soluble mediators in both immune cell activation and promoting a shift in TCam-2 cells from a seminoma-like phenotype to a more dedifferentiated phenotype, suggesting that cytokines critically shape the TME. These observations highlight the complexity of tumor-immune interactions in the seminoma microenvironment, offering new insight into immune-driven dynamics in TGCTs."

Journal • Preclinical • Germ Cell Tumors • Oncology • Solid Tumor • Testicular Cancer • Testicular Seminoma • IL6 • TNFA

Exploring total inflammatory vascular volume as a diagnostic and prognostic biomarkers in giant cell arteritis. (PubMed, Rheumatology (Oxford)) - P | "TIVV and TIGV showed superior diagnostic and prognostic performance compared with conventional PET parameters, underscoring the importance of inflammation volume in evaluating disease activity in LV-GCA.ClinicalTrials.gov ID NCT05394909."

Biomarker • Journal • Giant Cell Arteritis • Immunology • Inflammation • Vasculitis

Case Report: Can early full-course tocilizumab therapy reverse vascular stenosis in Takayasu arteritis? (PubMed, Front Immunol) - "In addition, we summarized the cases of improvement of vascular lesions after tocilizumab treatment of TAK, and preliminarily compared the efficacy and safety of tocilizumab and TNFi in TAK. We speculate that early and adequate use of tocilizumab could reverse early inflammatory vessel wall thickening and stenosis, and we found, through further literature review, that its efficacy was comparable to that of TNF inhibitors."

Journal • Cardiovascular • Hematological Disorders • Inflammation • Vasculitis

Management of side effects of CAR T cells (PubMed, Inn Med (Heidelb)) - "The management is stepwise using tocilizumab and corticosteroids depending on the severity, with recent data supporting the use of anakinra...Treatment includes anakinra, dexamethasone and other salvage medications, whereby recognition of the complication is essential...Prolonged cytopenia substantially increases the risk of infections and explains why infections are the most frequent non-disease-related cause of death after CAR T cell treatment. In summary, since the first approval the management of CAR T cell-related side effects has markedly improved through a better understanding of the pathophysiology, identification of risk factors and especially early intervention strategies."

Adverse events • Journal • Review • CNS Disorders • Cognitive Disorders • Epilepsy • Hematological Disorders • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Immunology • Infectious Disease • Inflammation • Oncology • Rare Diseases

Characterizing Cellular Expansion of Idecabtagene Vicleucel and Association with Clinical Efficacy and Safety in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma. (PubMed, J Clin Pharmacol) - P3 | "The multivariable E-R regression models suggest positive relationships between cellular expansion and clinical efficacy and safety endpoints, with higher exposure associated with longer PFS, higher ORR, and higher rates of cytokine release syndrome requiring tocilizumab or corticosteroids. The positive exposure-response relationships were found to be overall similar between KarMMa-3 and a previous study KarMMa. The modeling analyses, paired with clinical data, support extending the dose range from previously approved 300-460 × 106 CAR+ T cells to 300-510 × 106 CAR+ T cells for TCE RRMM patients."

Journal • Hematological Malignancies • Inflammation • Multiple Myeloma • Oncology

Efficacy and safety of tocilizumab in covid-19 critically ill patients: a multicenter cohort study (ERS 2025) - No abstract available

Clinical • Infectious Disease • Novel Coronavirus Disease

Tocilizumab Efficacy Across Inflammatory Subphenotypes in COVID-19 related ARDS (on behalf of the PANTHER CRC) (ERS 2025) - No abstract available

Clinical • Infectious Disease • Novel Coronavirus Disease

Treatment and monitoring of CTD-ILDs (ERS 2025) - "We describe recent advances in the treatment of CTD-ILD, including novel data and trials as well as post hoc analyses of clinical trials on mycophenolate, cyclophosmphamide, tocilizumab, rituximab, riociguat and nintedanib. Lastly, we elucidate on peripheral blood cell gene expression profiling as a novel way to identify patients with a better treatment response to mycophenolate."

Rheumatology

The cost-effectiveness of using vilobelimab with immunomodulators to treat severely ill mechanically ventilated patients with COVID-19: A subgroup analysis of the PANAMO study. (PubMed, Am J Health Syst Pharm) - "Vilobelimab therapy provides a cost-effective option to treat severely ill, mechanically ventilated patients with COVID-19 with prior and/or concomitant treatment with immunomodulators at a value well below the commonly accepted willingness-to-pay threshold of $50,000/QALY."

HEOR • Journal • Infectious Disease • Novel Coronavirus Disease • CFB

Rare Presentation of Adult-Onset Still's Disease Complicated by Acute Severe Hepatitis Refractory to Medical Treatment: A Case Report. (PubMed, Clin Case Rep) - "Standard treatments such as tocilizumab and rituximab can cause adverse reactions or lose efficacy. The interplay of systemic inflammation and liver involvement highlights the need for ongoing research to find effective, safe treatment alternatives."

Journal • Immunology • Inflammation

Therapy Sequencing in Relapsed/Refractory MCL (ICML 2025) - P1, P1/2, P2, P3 | "Although a direct comparison between them has only been performed for ibrutinib and temsirolimus [23], covalent BTK inhibitor (cBTKi) single agent therapy has been consolidated as the standard of care after first-line CIT. Moreover, to address cBTKi failure, two anti-CD19 CAR-T cell therapy products, brexucabtagene autoleucel [20, 21] and lisocabtagene maraleucel [22], and the first noncovalent BTKi, pirtobrutinib [19], have recently been approved...Liso-cel only FDA approved; CIT, chemoimmunotherapy options include BR, R-BAC, R-CHOP, R-DHAP or R-DHAOx, R-GEMOx, paliative options (avoid bendamustine pre-CART apheresis); pirtobrutinib, available after cBTKi failure in second-line (EMA) but third-line (FDA); RM, rituximab maintenance...Orelabrutinib [18] is licensed only in China...Of note, both acalabrutinib and zanubrutinib induce lower rates of atrial fibrillation, hypertension, and bleeding compared to ibrutinib in randomized studies..."

IO biomarker • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Mantle Cell Lymphoma • Oncology • PLCG2 • TP53

Non-Clonal Lymphoproliferative Diseases (ICML 2025) - P, P2 | "On rare occasions, the use of systemic therapy like siltuximab or rituximab may be of value to shrink a large lymph node, making a previously inoperable target operable...Data from the use of tocilizumab, an anti-IL-6 receptor antibody, which is approved for iMCD in Japan based on a single-arm, open-label study, would suggest that relapses occur upon cessation of therapy [32]...For patients with non-severe iMCD, options in the refractory setting that can be considered include corticosteroids, rituximab, thalidomide, lenalidomide, bortezomib, cyclosporine, sirolimus, interferon, as well as others [20, 24, 33-37]...A phase 2 study of oral thalidomide, cyclophosphamide, and prednisone in newly-diagnosed iMCD, 48% of patients responded [37]...For relapsed or refractory disease or concurrent KS, or life-threatening organ failure, rituximab plus either liposomal doxorubicin or etoposide are recommended [46, 49]...If not, treatment like other iMCD is appropriate...."

B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Plasmacytoma • CRP

Cytokine Release Syndrome Induced by Pembrolizumab for Metastatic Anal Melanoma. (PubMed, Case Rep Hematol) - "Cytokine release syndrome (CRS) is a rare systemic inflammatory response that can be triggered by certain drugs and infections, commonly diagnosed at a disseminated stage, leading to poor prognosis. Tocilizumab and steroids were successfully used and resulted in the resolution of symptoms without relapse. This case highlights the diagnostic and therapeutic challenges posed by immunotherapy-induced CRS and emphasizes the importance of early recognition to achieve good outcomes."

Journal • Hypotension • Immunology • Infectious Disease • Melanoma • Oncology • Septic Shock • Solid Tumor • Systemic Inflammatory Response Syndrome

Temporal arteritis and vasculitic myopathy in polyarteritis nodosa. (PubMed, J Neurol) - No abstract available

Journal • Giant Cell Arteritis • Immunology • Myositis • Vasculitis

Efficacy and Safety of Tocilizumab in Polymyalgia Rheumatica: A Systematic Review and Meta-analysis of Randomized Controlled Trials. (PubMed, ARP Rheumatol) - "Our findings indicate that tocilizumab significantly improved glucocorticoid-free remission rates and reduced the cumulative prednisolone dose at week 24. Notably, safety outcomes between tocilizumab and placebo groups were comparable. These findings support the efficacy of tocilizumab in treatment of PMR."

Clinical • Journal • Retrospective data • Review • Gastroenterology • Gastrointestinal Disorder • Giant Cell Arteritis • Immunology • Infectious Disease • Musculoskeletal Diseases • Musculoskeletal Pain • Pain • Rheumatology

The Clinical Efficacy and Safety of Nintedanib in the Treatment of Interstitial Lung Disease Among Patients With Systemic Sclerosis: Systematic Review. (PubMed, Can Respir J) - "Currently, treatment is chiefly directed toward impeding disease progression with the mainstay treatment approaches involving the utilization of cyclophosphamide, mycophenolate mofetil, rituximab, and tocilizumab. We searched PubMed, Scopus, and CENTRAL up to the first of September 2023 utilizing the following keywords: ((Diffuse Parenchymal Lung Disease) OR (Diffuse Parenchymal Lung Diseases) OR (Interstitial Lung Disease) OR (Interstitial Lung Diseases) OR (Interstitial Pneumonia) OR (Interstitial Pneumonitis) OR (Pulmonary Fibrosis)) AND ((Systemic Scleroderma) OR (Systemic Scleroderma)) AND ((BIBF 1120) OR (BIBF-1120) OR (BIBF1120) OR (Nintedanib esylate) OR (Ofev) OR (Vargatef)). The clinical safety profile of nintedanib was deemed more favorable than other therapeutic regimens currently utilized, in addition to adequate clinical efficacy toward SSc-ILD."

Journal • Review • Cardiovascular • Fibrosis • Immunology • Infectious Disease • Inflammation • Interstitial Lung Disease • Metabolic Disorders • Pneumonia • Pulmonary Disease • Respiratory Diseases • Rheumatology • Scleroderma • Systemic Sclerosis